Cost-Effectiveness of Tamsulosin, Doxazosin, and Terazosin in the Treatment of Benign Prostatic Hyperplasia

OBJECTIVES: To evaluate the cost-effectiveness of tamsulosin, doxazosin, or terazosin as initial treatments for moderate benign prostatic hyperplasia (BPH) over a 3-year time horizon from a health-system-payer perspective. METHODS: A decision-analytic model is used to project the course of treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohsfeldt, Robert L., Kreder, Karl J., Klein, Robert W., Chrischilles, Elizabeth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2004
Materias:
Formulary Management
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437807/
https://www.ncbi.nlm.nih.gov/pubmed/15369424
http://dx.doi.org/10.18553/jmcp.2004.10.5.412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437807/
https://www.ncbi.nlm.nih.gov/pubmed/15369424
http://dx.doi.org/10.18553/jmcp.2004.10.5.412

Ejemplares similares